Importantly, the CAR’s structure enables CAR-T cells to target and eliminate tumor cells independently of major histocompatibility complex (MHC) recognition achieved through the direct interaction between the scFv and tumor-associated antigens, thus overcoming immune evasion often linked to low MHC expression within tumor sites [6]. Here, HLA-C is linked to neoplasm.